Roivant director sells 1,638,163 shares
Roivant Sciences director Keith S. Manchester reported open-market sales totaling 1,638,163 Common Shares of Roivant Sciences Ltd. from June 26–30, 2026, at prices between $33.92 and $35.45 per share.
Rhea-AI Filing Summary
Roivant Sciences director Keith S. Manchester reported open-market sales totaling 1,638,163 Common Shares of Roivant Sciences Ltd. from June 26–30, 2026, at prices between $33.92 and $35.45 per share. The filing shows 200,000 shares sold from his direct holdings, leaving 1,748,403 shares held directly, and additional sales by QVT Financial Investment Cayman Ltd., which held 13,689,166 shares afterward. Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of those shares except for his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Director reports sizable net share sales while retaining large holdings.
Director Keith S. Manchester reported six open-market sale transactions in Roivant Sciences Ltd. Common Shares totaling 1,638,163 shares between June 26 and June 30, 2026. These are all non-derivative transactions coded "S", indicating straightforward open-market or private sales.
The filing separates 200,000 shares sold from Manchester’s direct holdings from 1,438,163 shares sold by QVT Financial Investment Cayman Ltd.. A footnote states he is a shareholder of this entity but has no voting or investment control and disclaims beneficial ownership beyond his pecuniary interest, which limits how directly these trades reflect his own portfolio decisions.
After the transactions, Manchester’s direct position is 1,748,403 shares, and QVT Financial Investment Cayman Ltd. shows 13,689,166 shares. The sales are material in absolute terms, but the remaining positions suggest continued substantial exposure. The filing does not reference any Rule 10b5-1 trading plan, so these appear as discretionary sales based on the disclosed information.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares | 12,380 | $35.28 | $437K |
| Sale | Common Shares | 200,000 | $35.45 | $7.09M |
| Sale | Common Shares | 200,000 | $34.44 | $6.89M |
| Sale | Common Shares | 600,000 | $34.59 | $20.75M |
| Sale | Common Shares | 300,783 | $33.92 | $10.20M |
| Sale | Common Shares | 325,000 | $34.07 | $11.07M |
Footnotes (1)
- F1. The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Key Figures
Key Terms
open-market sale financial
Section 16 regulatory
beneficial ownership financial
pecuniary interest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Roivant Sciences (ROIV) disclose in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.